CL2003001360A1 - Compuestos derivados de pirazol, composicion farmaceutica, agonistas o antagonistas selectivos dl receptor cck-1, utiles para el tratamiento de trastornos gastrointestinales y del sistema nervioso central. - Google Patents

Compuestos derivados de pirazol, composicion farmaceutica, agonistas o antagonistas selectivos dl receptor cck-1, utiles para el tratamiento de trastornos gastrointestinales y del sistema nervioso central.

Info

Publication number: CL2003001360A1
Authority: CL; Chile
Prior art keywords: pirazol; cck; agonists; receiver; useful
Prior art date: 2002-07-03

Application number

CL200301360A

Other languages

English (en)

Inventor

Terrance Gomez Laurent Barrett

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-07-03

Filing date

2003-07-03

Publication date

2005-06-03

2003-07-03 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2005-06-03 Publication of CL2003001360A1 publication Critical patent/CL2003001360A1/es

Links

208000018522 Gastrointestinal disease Diseases 0.000 title 1
239000000556 agonist Substances 0.000 title 1
239000005557 antagonist Substances 0.000 title 1
210000003169 central nervous system Anatomy 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Diabetes (AREA)
Addiction (AREA)
Child & Adolescent Psychology (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Nutrition Science (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Investigating Or Analysing Biological Materials (AREA)
Pyridine Compounds (AREA)

CL200301360A 2002-07-03 2003-07-03 Compuestos derivados de pirazol, composicion farmaceutica, agonistas o antagonistas selectivos dl receptor cck-1, utiles para el tratamiento de trastornos gastrointestinales y del sistema nervioso central. CL2003001360A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US39349302P	2002-07-03	2002-07-03

Publications (1)

Publication Number	Publication Date
CL2003001360A1 true CL2003001360A1 (es)	2005-06-03

Family

ID=30115589

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL200301360A CL2003001360A1 (es)	2002-07-03	2003-07-03	Compuestos derivados de pirazol, composicion farmaceutica, agonistas o antagonistas selectivos dl receptor cck-1, utiles para el tratamiento de trastornos gastrointestinales y del sistema nervioso central.

Country Status (22)

Country	Link
US (2)	US7037931B2 (es)
EP (1)	EP1525190A1 (es)
JP (1)	JP2006501194A (es)
KR (1)	KR20050042130A (es)
CN (1)	CN100522947C (es)
AR (1)	AR041183A1 (es)
AU (1)	AU2003253776A1 (es)
BR (1)	BR0312378A (es)
CA (1)	CA2491213A1 (es)
CL (1)	CL2003001360A1 (es)
CO (1)	CO5400148A1 (es)
EA (1)	EA009479B1 (es)
HR (1)	HRP20041224A2 (es)
IL (1)	IL166069A0 (es)
MX (1)	MXPA05000204A (es)
NO (1)	NO20050498L (es)
NZ (1)	NZ537899A (es)
PL (1)	PL374757A1 (es)
TW (1)	TW200418469A (es)
UA (1)	UA79804C2 (es)
WO (1)	WO2004007463A1 (es)
ZA (1)	ZA200500973B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA79804C2 (en)	2002-07-03	2007-07-25	Janssen Pharmaceutica Nv	Cck-1 receptor modulators
CA2522687A1 (en)	2003-04-18	2004-11-04	Memory Pharmaceuticals Corporation	Pyrazole derivatives as phosphodiesterase 4 inhibitors
US20050020565A1 (en) *	2003-07-02	2005-01-27	Jones Todd K.	CCK-1 receptor modulators
RU2005141571A (ru) *	2003-07-02	2007-07-10	Янссен Фармацевтика Н.В. (Be)	Модуляторы рецептора сск-1
WO2005063716A1 (en) *	2003-12-22	2005-07-14	Janssen Pharmaceutica, N.V.	Imidazoles and their use cck-1 receptor modulators
MXPA06014551A (es) *	2004-06-30	2007-06-05	Johnson & Johnson	Esteres y acidos alfa,beta no saturados mediante deshidratacion estereoselectiva.
CN101166733A (zh)	2004-10-15	2008-04-23	记忆药物公司	作为磷酸二酯酶4抑制剂的吡唑衍生物
US20060177438A1 (en) *	2005-02-08	2006-08-10	New England Medical Center	Methods of altering absorption of hydrophobic compounds
EP2010178B1 (en) *	2006-04-14	2010-09-01	Merck Sharp & Dohme Corp.	Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators
WO2007120718A2 (en) *	2006-04-14	2007-10-25	Merck & Co., Inc.	Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators
JP5986098B2 (ja) *	2010-11-24	2016-09-06	ザオハイオステートユニバーシティーリサーチファウンデーション	インテグリン結合キナーゼ阻害剤
RU2693484C1 (ru)	2013-11-22	2019-07-03	СиЭль БАЙОСАЕНСИЗ ЭлЭлСи	Антагонисты гастрина для лечения и профилактики остеопороза
CA2929785C (en)	2013-12-13	2018-02-13	F. Hoffmann-La Roche Ag	Inhibitors of bruton's tyrosine kinase
RU2648236C2 (ru)	2013-12-13	2018-03-23	Ф. Хоффманн-Ля Рош Аг	Ингибиторы тирозинкиназы брутона

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4826868A (en) *	1986-05-29	1989-05-02	Ortho Pharmaceutical Corporation	1,5-Diaryl-3-substituted pyrazoles pharmaceutical compositions and use
US5164381A (en) *	1986-05-29	1992-11-17	Ortho Pharmaceutical Corporation	Pharmacologically active 1,5-diaryl-3-substituted pyrazoles and method for synthesizing the same
US5051518A (en) *	1987-05-29	1991-09-24	Ortho Pharmaceutical Corporation	Pharmacologically active 2- and 3-substituted (1',5'-diaryl-3-pyrazolyl)-N-hydroxypropanamides
AU611437B2 (en) *	1987-05-29	1991-06-13	Ortho Pharmaceutical Corporation	Pharmacologically active 2- and 3-substituted (1',5'-diaryl-3-pyrazolyl)-n-hydroxypropanamides and method for synthesizing the same
ZA915372B (en) *	1990-07-17	1993-03-31	Lilly Co Eli	Pyrazolidinone cck and gastrin antagonists and pharmaceutical formulations thereof
PL181782B1 (pl)	1993-08-10	2001-09-28	Black James Foundation	Nowe zwiazki i sposób wytwarzania nowych zwiazków PL
US5756529A (en)	1995-09-29	1998-05-26	G.D. Searle & Co.	Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies
JPH09151183A (ja) *	1995-12-01	1997-06-10	Yoshitomi Pharmaceut Ind Ltd	チエニルアミド化合物
DE19621687A1 (de)	1996-05-30	1997-12-04	Bayer Ag	Verfahren zur Herstellung von substituierten Arylpyrazolen
US7235658B2 (en)	2000-03-06	2007-06-26	Smithkline Beecham P.L.C.	Imidazol derivatives as Raf kinase inhibitors
GB0011092D0 (en)	2000-05-08	2000-06-28	Black James Foundation	Gastrin and cholecystokinin receptor ligands (III)
GB0011095D0 (en)	2000-05-08	2000-06-28	Black James Foundation	astrin and cholecystokinin receptor ligands (III)
GB0011089D0 (en)	2000-05-08	2000-06-28	Black James Foundation	Gastrin and cholecystokinin receptor ligands (11)
GB0016787D0 (en) *	2000-07-07	2000-08-30	Pfizer Ltd	Compounds useful in therapy
EP1338603B1 (en) *	2000-11-02	2010-01-20	Ajinomoto Co., Inc.	Novel pyrazole derivatives and diabetes remedies containing the same
US6784185B2 (en) *	2001-03-16	2004-08-31	Pfizer Inc.	Pharmaceutically active compounds
JP2004530690A (ja) *	2001-05-16	2004-10-07	ベーリンガーインゲルハイムファーマシューティカルズインコーポレイテッド	抗炎症性薬剤として有用なジアリールウレア誘導体
CA2456192A1 (en) *	2001-08-03	2003-02-13	Qing Tang	Pyrazole-derived kinase inhibitors and uses thereof
CA2456187A1 (en) *	2001-08-03	2003-02-13	Qing Tang	Pyrazole-derived kinase inhibitors and uses thereof
US6906196B2 (en)	2001-09-18	2005-06-14	Onconova Therapeutics, Inc.	Processes for the preparation of 1,5-diaryl-3-substituted-pyrazoles
EP1438293A2 (en) *	2001-09-19	2004-07-21	Pharmacia Corporation	Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation
WO2003037336A1 (en) *	2001-11-02	2003-05-08	Pfizer Products Inc.	1-(5-sulfonyl-pyridin-2-yl)-5-(methylidene-cycloalkylmethoxy)-1h-pyrazole-4-carbonitrile derivatives and other compounds as cyclooxygenase inhibitors for the treatment of arthritis, neurodegeneration and colon cancer
EP1551794A4 (en) *	2002-06-19	2006-05-17	Bristol Myers Squibb Co	UREIDO-SUBSTITUTED ANILINE COMPOUNDS SUITABLE AS SERINPROTEASE INHIBITORS
UA79804C2 (en)	2002-07-03	2007-07-25	Janssen Pharmaceutica Nv	Cck-1 receptor modulators

2003
- 2003-02-07 UA UAA200500955A patent/UA79804C2/uk unknown
- 2003-07-02 PL PL03374757A patent/PL374757A1/xx not_active Application Discontinuation
- 2003-07-02 US US10/612,150 patent/US7037931B2/en not_active Expired - Lifetime
- 2003-07-02 EP EP03764341A patent/EP1525190A1/en not_active Withdrawn
- 2003-07-02 JP JP2004521518A patent/JP2006501194A/ja active Pending
- 2003-07-02 EA EA200401621A patent/EA009479B1/ru not_active IP Right Cessation
- 2003-07-02 BR BR0312378-2A patent/BR0312378A/pt not_active IP Right Cessation
- 2003-07-02 WO PCT/US2003/020787 patent/WO2004007463A1/en active Application Filing
- 2003-07-02 AU AU2003253776A patent/AU2003253776A1/en not_active Abandoned
- 2003-07-02 KR KR1020057000056A patent/KR20050042130A/ko not_active Ceased
- 2003-07-02 NZ NZ537899A patent/NZ537899A/en unknown
- 2003-07-02 MX MXPA05000204A patent/MXPA05000204A/es active IP Right Grant
- 2003-07-02 CA CA002491213A patent/CA2491213A1/en not_active Abandoned
- 2003-07-02 CN CNB038207613A patent/CN100522947C/zh not_active Expired - Fee Related
- 2003-07-03 CL CL200301360A patent/CL2003001360A1/es unknown
- 2003-07-03 AR ARP030102418A patent/AR041183A1/es unknown
- 2003-07-03 CO CO03056084A patent/CO5400148A1/es not_active Application Discontinuation
- 2003-07-03 TW TW092118137A patent/TW200418469A/zh unknown
2004
- 2004-12-29 HR HR20041224A patent/HRP20041224A2/xx not_active Application Discontinuation
- 2004-12-30 IL IL16606904A patent/IL166069A0/xx unknown
2005
- 2005-01-28 NO NO20050498A patent/NO20050498L/no not_active Application Discontinuation
- 2005-02-02 ZA ZA200500973A patent/ZA200500973B/en unknown
- 2005-09-19 US US11/230,200 patent/US7465808B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
US7037931B2 (en)	2006-05-02
HRP20041224A2 (en)	2007-03-31
JP2006501194A (ja)	2006-01-12
UA79804C2 (en)	2007-07-25
ZA200500973B (en)	2006-04-26
CN1678587A (zh)	2005-10-05
EA009479B1 (ru)	2008-02-28
US7465808B2 (en)	2008-12-16
WO2004007463A1 (en)	2004-01-22
IL166069A0 (en)	2006-01-15
CO5400148A1 (es)	2004-05-31
MXPA05000204A (es)	2005-09-30
KR20050042130A (ko)	2005-05-04
CN100522947C (zh)	2009-08-05
EP1525190A1 (en)	2005-04-27
PL374757A1 (en)	2005-10-31
CA2491213A1 (en)	2004-01-22
US20060014817A1 (en)	2006-01-19
AU2003253776A1 (en)	2004-02-02
NZ537899A (en)	2007-04-27
AR041183A1 (es)	2005-05-04
NO20050498L (no)	2005-03-16
EA200401621A1 (ru)	2005-06-30
TW200418469A (en)	2004-10-01
BR0312378A (pt)	2005-04-26
US20040067983A1 (en)	2004-04-08

Publication	Publication Date	Title
CL2003001360A1 (es)	2005-06-03	Compuestos derivados de pirazol, composicion farmaceutica, agonistas o antagonistas selectivos dl receptor cck-1, utiles para el tratamiento de trastornos gastrointestinales y del sistema nervioso central.
CL2006003736A1 (es)	2008-05-16	Compuestos derivados de triazina o pirimidina sustituida, antagonistas del receptor de prokineticina 1, composicion farmaceutica; y uso en el tratamiento de trastornos gastrointestinales.
CL2004000526A1 (es)	2005-03-18	Compuestos derivados de dibenzofurano, carbazoles, inhibidores de fosfodiesterasa tipo 4; procedimiento de preparacion; y su uso en el tratamiento de trastornos y condiciones inflamatorias, del sistema nervioso central y diabetes insulino resistente.
CL2007002578A1 (es)	2008-07-04	Compuestos derivados de n-(1-ftalazin-1-il-piperidin-4-il)-amidas; composicion farmaceutica; y uso para el tratamiento y prevencion de trastornos de la fertilidad, osteoporosis y cancer.
NO20052496D0 (no)	2005-05-24	Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter.
CL2004001069A1 (es)	2005-04-01	Compuestos derivados de 1-benzoil-isoquinolinas sustituidos; procedimiento de preparacion, composicion farmaceutica; y uso para el tratamiento o profilaxis de diabetes tipo ii.
CL2007003266A1 (es)	2008-07-04	Compuestos derivados de progesterona, antagonistas del receptor de progesterona; composicion farmaceutica; y uso para el tratamiento de endometriosis, miomas o tumores dependientes de hormonas.
CL2008003595A1 (es)	2009-11-20	Compuestos heterociclicos nitrogenados, antagonistas del receptor de taquiquinina; agente farmaceutico que comprende el compuesto; y uso en la profilaxis o el tratamiento de una enfermedad del tracto urinario inferior, una enfermedad gastrointestinal o una enfermedad del sistema nervioso central.
WO2008077557A8 (en)	2009-05-22	8-ethinylxanthine derivatives as selective a2a receptor antagonists
ATE526318T1 (de)	2011-10-15	Farnesoid-x-rezeptor-agonisten
NO20034122D0 (no)	2003-09-16	Sammensmeltede pyridinderivater for anvendelse som vanilloidreseptorantagonister for behandling av smerte
CL2007002356A1 (es)	2008-04-18	Sistema de liberacion farmaceutica que comprende flibanserina y por lo menos un excipiente farmaceuticamentre aceptable; y su uso para el tratamiento de trastornos del sistema nervioso central, trastornos afectivos, del sueno y sexuales, entre otros.
CL2004000868A1 (es)	2005-01-21	Compuestos derivados de acidos carboxilicos, antagonistas del receptor de calcio 8casr); composiciones farmaceuticas que comprenden el compuesto, utiles para el tratamiento de osteoporosis.
BRPI0615163A2 (pt)	2016-09-13	composto, composição farmacêutica, uso do composto, e, métodos de tratamento de distúrbios mediados por mglur5 e para inibição da ativação de receptores de mglur5
CY1111977T1 (el)	2015-11-04	Παραγωγα πιπεριδιν-4-υλ-πυριδαζιν-3-υλαμινης ως ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2
DK1377586T3 (da)	2006-07-10	Tricykliske diazepiner som tocolytiske oxytocinreceptorantagonister
CL2007003183A1 (es)	2008-06-27	Compuestos biciclicos puenteados; y composicion farmaceutica, util para el tratamiento de trastornos del apetito, diabetes y obesidad entre otros.
ZA200702397B (en)	2008-10-29	Benzoxasine and quinoxaline derivatives and uses
CL2004000695A1 (es)	2005-02-04	Compuestos derivados de 4-fenil piperidina, composicion farmaceutica, util como modulador del receptor opioides, para tratar sindrome de intestino irritable, adiccion o dependencia de drogas, depresion, ansiedad, esquizofrenia, trastornos de la alime
CL2007002643A1 (es)	2008-04-18	Compuestos derivados de 5-fenil-nicotinamida, moduladores del receptor de cb1; procedimiento de preparacion; composiciones farmaceuticas; y uso para el tratamiento y/o profilaxis de trastornos de la nutricion, diabetes tipo ii y dependencia de sustan
WO2000077008A3 (en)	2001-04-19	Heteroaryl substituted piperidines as gaba brain receptor lingands
AR028579A1 (es)	2003-05-14	Metodo para el tratamiento de la sequedad vaginal, con agonistas del receptor de acetilcolina nicotinica
CL2007003198A1 (es)	2008-02-15	Compuestos diarilicos opcionalmente nitrogenados, antagonistas de los receptores opioides; composicion farmaceutica; y uso en el tratamiento de la obesidad.
CL2007002511A1 (es)	2008-05-16	Compuestos derivados de pirrolo[2,3-f]isoquinolina, inhibidores de cinasa-2; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; y uso para el tratamiento de una enfermedad autoinmune.
DE60314896D1 (de)	2007-08-23	5-ht 1b/1d rezeptor agonisten zur behandlung von kopfschmerz der aus der verabreichung von endothelin rezeptor antagonisten resultiert